Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

388 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region.
Ishikawa Y, Tanaka N, Asano Y, Kodera M, Shirai Y, Akahoshi M, Hasegawa M, Matsushita T, Saito K, Motegi SI, Yoshifuji H, Yoshizaki A, Kohmoto T, Takagi K, Oka A, Kanda M, Tanaka Y, Ito Y, Nakano K, Kasamatsu H, Utsunomiya A, Sekiguchi A, Niiro H, Jinnin M, Makino K, Makino T, Ihn H, Yamamoto M, Suzuki C, Takahashi H, Nishida E, Morita A, Yamamoto T, Fujimoto M, Kondo Y, Goto D, Sumida T, Ayuzawa N, Yanagida H, Horita T, Atsumi T, Endo H, Shima Y, Kumanogoh A, Hirata J, Otomo N, Suetsugu H, Koike Y, Tomizuka K, Yoshino S, Liu X, Ito S, Hikino K, Suzuki A, Momozawa Y, Ikegawa S, Tanaka Y, Ishikawa O, Takehara K, Torii T, Sato S, Okada Y, Mimori T, Matsuda F, Matsuda K, Amariuta T, Imoto I, Matsuo K, Kuwana M, Kawaguchi Y, Ohmura K, Terao C. Ishikawa Y, et al. Among authors: utsunomiya a. Nat Commun. 2024 Jan 31;15(1):319. doi: 10.1038/s41467-023-44541-z. Nat Commun. 2024. PMID: 38296975 Free PMC article.
A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects.
Utsunomiya A, Oyama N, Iino S, Baba N, Chino T, Utsunomiya N, Hasegawa M. Utsunomiya A, et al. Among authors: utsunomiya n. Case Rep Dermatol. 2018 Jan 18;10(1):1-6. doi: 10.1159/000485910. eCollection 2018 Jan-Apr. Case Rep Dermatol. 2018. PMID: 29515387 Free PMC article.
Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX3 CL1/CX3 CR1 Pathway in Experimental Mouse Models of Systemic Sclerosis.
Luong VH, Utsunomiya A, Chino T, Doanh LH, Matsushita T, Obara T, Kuboi Y, Ishii N, Machinaga A, Ogasawara H, Ikeda W, Kawano T, Imai T, Oyama N, Hasegawa M. Luong VH, et al. Among authors: utsunomiya a. Arthritis Rheumatol. 2019 Nov;71(11):1923-1934. doi: 10.1002/art.41009. Epub 2019 Sep 11. Arthritis Rheumatol. 2019. PMID: 31173491
Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model.
Hasegawa T, Utsunomiya A, Chino T, Kasamatsu H, Shimizu T, Matsushita T, Obara T, Ishii N, Ogasawara H, Ikeda W, Imai T, Oyama N, Hasegawa M. Hasegawa T, et al. Among authors: utsunomiya a. Arthritis Res Ther. 2024 May 3;26(1):94. doi: 10.1186/s13075-024-03307-8. Arthritis Res Ther. 2024. PMID: 38702742 Free PMC article.
388 results